

**ANTIDEPRESSANTS, OTHER
PRIOR AUTHORIZATION FORM**
(form effective 7/15/2024)



Fax to PerformRxSM at **1-888-981-5202**, or to speak to a representative call **1-866-610-2774**.

PRIOR AUTHORIZATION REQUEST INFORMATION			
<input type="checkbox"/> New request <input type="checkbox"/> Renewal request		Total # of pages:	
Name of office contact:		Contact's phone number:	LTC facility contact/phone:
BENEFICIARY INFORMATION			
Beneficiary name:		Beneficiary ID#:	DOB:
Street address:			
Apt #:	City/state/zip:		Phone:
PRESCRIBER INFORMATION			
Prescriber name:			
Specialty:		NPI:	State license #:
Street address:			
Suite #:	City/state/zip:		
Phone:		Fax:	
CLINICAL INFORMATION			
Drug requested:			
Strength:		Dosage form:	
Dose and directions:		Quantity:	Refills:
Diagnosis (<i>submit documentation</i>):			Dx code (<i>required</i>):
Is the beneficiary currently being treated with the requested medication?			<input type="checkbox"/> Yes – <i>date of last dose:</i> <input type="checkbox"/> No <i>Submit documentation.</i>
INITIAL REQUESTS			
Complete all sections that apply to the beneficiary and this request. Check all that apply and <i>submit documentation</i> for each item.			
1. For ZULRESSO (brexanolone) and ZURZUVAE (zuranolone): <input type="checkbox"/> Is being treated for postpartum depression (PPD) AND: <input type="checkbox"/> Has depression with onset in the 3rd trimester through 4 weeks postpartum. <input type="checkbox"/> Has moderate to severe PPD based on a validated depression rating scale (e.g., PHQ-9/EPDS, HAMD-17). <input type="checkbox"/> Is less than or equal to 12 months postpartum. <input type="checkbox"/> Is not actively psychotic, manic, or hypomanic. <input type="checkbox"/> Is not currently pregnant.			
2. For ALL OTHER NON-PREFERRED Antidepressants, Other (except Zulresso and Zurzuvae): <input type="checkbox"/> Tried and failed or has a contraindication or an intolerance to the <u>preferred Antidepressants, Other</u> that are FDA-approved or medically accepted for the treatment of the beneficiary's diagnosis at maximally tolerated doses for at least 6 weeks. (<i>Refer to https://papdl.com/preferred-drug-list for a list of preferred Antidepressants, Other.</i>) List preferred medications tried: _____ <input type="checkbox"/> Tried and failed or has a contraindication or an intolerance to the <u>Antidepressants, SSRIs</u> that are FDA-approved or medically accepted for the treatment of the beneficiary's diagnosis at maximally tolerated doses for at least 6 weeks. <input type="checkbox"/> citalopram (e.g., Celexa) <input type="checkbox"/> escitalopram (e.g., Lexapro) <input type="checkbox"/> fluoxetine (e.g., Prozac, Sarafem) <input type="checkbox"/> fluvoxamine (e.g., Luvox) <input type="checkbox"/> paroxetine (e.g., Paxil, Pexeva) <input type="checkbox"/> sertraline (e.g., Zoloft) <input type="checkbox"/> Tried and failed or has a contraindication or an intolerance to <u>augmentation therapy</u> (e.g., lithium, antipsychotic, stimulant) <u>in combination with an antidepressant</u> that is FDA-approved or medically accepted for the treatment of the beneficiary's diagnosis at maximally tolerated doses for at least 6 weeks. List preferred medications tried: _____			
3. For SPRAVATO (esketamine): <input type="checkbox"/> Is prescribed Spravato by or in consultation with a psychiatrist. <input type="checkbox"/> Will use Spravato in conjunction with a therapeutic dose of an oral antidepressant. <input type="checkbox"/> Does not have severe hepatic impairment (Child-Pugh class C).			



RENEWAL REQUESTS

1. For SPRAVATO (esketamine):

- Is prescribed Spravato by or in consultation with a psychiatrist.
- Will use Spravato in conjunction with a therapeutic dose of an oral antidepressant.
- Does not have severe hepatic impairment (Child-Pugh class C).
- Has documentation of improvement in disease severity since starting treatment.

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION

Prescriber signature:

Date:

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or taking of any telecopy is strictly prohibited.